| Dr Theodore L Fellenbaum, MD | |
|
4520 Linden Creek Pkwy, Suite F, Flint, MI 48507-2969 | |
| (810) 733-8200 | |
| (810) 733-8272 |
| Full Name | Dr Theodore L Fellenbaum |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 48 Years |
| Location | 4520 Linden Creek Pkwy, Flint, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366457848 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 4301056913 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dr. T. Fellenbaum M.d. And Ob/gyn Associates, P.c. | 6103992078 | 2 |
News Archive
Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.
Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). This is the first licence worldwide of BOTOX® for this indication, and is also the first prophylactic (preventative) treatment to receive a specific licence for patients with chronic migraine.
Researchers at Cold Spring Harbor Laboratory (CSHL) announced today the discovery of a new class of small RNAs. At the same time, they reported that their discovery suggests the presence of a strikingly novel biochemical pathway for RNA processing in which these and possibly other small RNAs are produced.
The Council of Ministers in southern Sudan on Friday passed a resolution to streamline HIV/AIDS programs at all ministries and independent commissions, as well as at the state level, the Sudan Tribune reports.
Research led by Ludwine Messiaen, Ph.D., professor of genetics at the University of Alabama at Birmingham, shows that missense mutations in a cluster of just five codons in the NF1 gene are an important risk factor for severe symptoms of the genetic disease neurofibromatosis type 1.
› Verified 5 days ago
| Entity Name | Hurley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982630844 PECOS PAC ID: 2961308481 Enrollment ID: O20031208000375 |
News Archive
Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.
Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). This is the first licence worldwide of BOTOX® for this indication, and is also the first prophylactic (preventative) treatment to receive a specific licence for patients with chronic migraine.
Researchers at Cold Spring Harbor Laboratory (CSHL) announced today the discovery of a new class of small RNAs. At the same time, they reported that their discovery suggests the presence of a strikingly novel biochemical pathway for RNA processing in which these and possibly other small RNAs are produced.
The Council of Ministers in southern Sudan on Friday passed a resolution to streamline HIV/AIDS programs at all ministries and independent commissions, as well as at the state level, the Sudan Tribune reports.
Research led by Ludwine Messiaen, Ph.D., professor of genetics at the University of Alabama at Birmingham, shows that missense mutations in a cluster of just five codons in the NF1 gene are an important risk factor for severe symptoms of the genetic disease neurofibromatosis type 1.
› Verified 5 days ago
| Entity Name | Dr. T. Fellenbaum M.d. & Ob/gyn Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316114549 PECOS PAC ID: 6103992078 Enrollment ID: O20080829000560 |
News Archive
Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.
Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). This is the first licence worldwide of BOTOX® for this indication, and is also the first prophylactic (preventative) treatment to receive a specific licence for patients with chronic migraine.
Researchers at Cold Spring Harbor Laboratory (CSHL) announced today the discovery of a new class of small RNAs. At the same time, they reported that their discovery suggests the presence of a strikingly novel biochemical pathway for RNA processing in which these and possibly other small RNAs are produced.
The Council of Ministers in southern Sudan on Friday passed a resolution to streamline HIV/AIDS programs at all ministries and independent commissions, as well as at the state level, the Sudan Tribune reports.
Research led by Ludwine Messiaen, Ph.D., professor of genetics at the University of Alabama at Birmingham, shows that missense mutations in a cluster of just five codons in the NF1 gene are an important risk factor for severe symptoms of the genetic disease neurofibromatosis type 1.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Theodore L Fellenbaum, MD 4520 Linden Creek Pkwy, Suite F, Flint, MI 48507-2969 Ph: (810) 733-8200 | Dr Theodore L Fellenbaum, MD 4520 Linden Creek Pkwy, Suite F, Flint, MI 48507-2969 Ph: (810) 733-8200 |
News Archive
Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.
Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). This is the first licence worldwide of BOTOX® for this indication, and is also the first prophylactic (preventative) treatment to receive a specific licence for patients with chronic migraine.
Researchers at Cold Spring Harbor Laboratory (CSHL) announced today the discovery of a new class of small RNAs. At the same time, they reported that their discovery suggests the presence of a strikingly novel biochemical pathway for RNA processing in which these and possibly other small RNAs are produced.
The Council of Ministers in southern Sudan on Friday passed a resolution to streamline HIV/AIDS programs at all ministries and independent commissions, as well as at the state level, the Sudan Tribune reports.
Research led by Ludwine Messiaen, Ph.D., professor of genetics at the University of Alabama at Birmingham, shows that missense mutations in a cluster of just five codons in the NF1 gene are an important risk factor for severe symptoms of the genetic disease neurofibromatosis type 1.
› Verified 5 days ago
Dr. Larry J Young, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Two Hurley Plaza, Suite 204, Flint, MI 48503 Phone: 810-262-6743 Fax: 810-235-1210 | |
Dr. David H Pyatt, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 725 Mason St, Flint, MI 48503 Phone: 810-496-5777 | |
Anton Strocel, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1402 W Court St, Flint, MI 48503 Phone: 810-767-3220 Fax: 810-767-7969 | |
Sierra Cuthpert, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Hurley Plz, Flint, MI 48503 Phone: 810-262-6426 | |
Alexey A Levashkevich, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1010 N Linden Rd, Flint, MI 48532 Phone: 810-732-3660 Fax: 810-732-1082 | |
Dr. Phillip H. Hardy Jr., M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1 Hurley Plz, Flint, MI 48503 Phone: 810-257-9000 Fax: 810-760-0440 | |
Dr. Lauryn Lynn Przeslawski, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1314 S Linden Rd, Flint, MI 48532 Phone: 810-342-1700 Fax: 810-720-4035 |